Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Predicts Exubera, Chantix Favorable Reimbursement Despite Delays

Executive Summary

Pfizer's Chantix and Exubera are being favorably received by payers in early formulary discussions, Senior VP-Global Pharmaceutical Finance Peter Brandt said during the company's second quarter earnings call July 20

You may also be interested in...



As Pfizer Closes Door On Exubera, Has Window Opened For Others?

Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer

As Pfizer Closes Door On Exubera, Has Window Opened For Others?

Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer

Pfizer Plans Exubera “Full Court Press”’ In 2007 After 2006 Stumbles

Pfizer is finally ramping up for a full-scale launch of the inhaled insulin Exubera - targeting primary care physicians and consumers - over one year after the drug was approved by FDA

Related Content

UsernamePublicRestriction

Register

PS047412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel